Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NewAmsterdam Pharma Company ( (NAMS) ) has issued an announcement.
NewAmsterdam Pharma has announced promising results from its Phase 3 BROADWAY trial, revealing that obicetrapib significantly reduces LDL cholesterol levels and major adverse cardiovascular events in patients with cardiovascular disease. The trial demonstrated a 33% reduction in LDL-C and a 21% reduction in cardiovascular events, with obicetrapib being well-tolerated, comparing favorably to placebo. These findings suggest obicetrapib could offer a new, effective oral treatment for those struggling to manage cholesterol levels despite existing therapies.
Find detailed analytics on NAMS stock on TipRanks’ Stock Analysis page.